Bridging differences in outcomes of pharmacoepidemiological studies: Design and first results of the PROTECT project

Current Clinical Pharmacology

Volumn 9, Issue 2, 2014, Pages 130-138

  Abbing Karahagopian, Victoria ^a   Kurz, Xavier ^b   de Vries, Frank ^a,c   van Staa, Tjeerd P ^a,d   Alvarez, Yolanda ^b   Hesse, Ulrik ^e   Hasford, Joerg ^f   van Dijk, Liset ^a,g   de Abajo, Francisco J ^h   Weil, John G ⁱ   Grimaldi Bensouda, Lamiae ^j   Egberts, Antoine C G ^a,k   Reynolds, Robert F ^l   Klungel, Olaf H ^a,k  

^a UTRECHT UNIVERSITY   (Netherlands)

^b EUROPEAN MEDICINES AGENCY   (United Kingdom)

^c MAASTRICHT UNIVERSITY   (Netherlands)

^d MEDICINES AND HEALTHCARE PRODUCTS REGULATORY AGENCY   (United Kingdom)

^e National Institute for Health Data and Disease Control Sector for National Health Documentation and Research ^*  (Denmark)

^f UNIVERSITY OF MUNICH   (Germany)

^g NETHERLANDS INSTITUTE FOR HEALTH SERVICES RESEARCH   (Netherlands)

^h UNIVERSITY OF ALCALÁ   (Spain)

ⁱ GLAXOSMITHKLINE   (United Kingdom)

^j University Versailles Saint Quentin UVSQ   (France)

^k UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^l PFIZER INC   (United States)

more..

Author keywords

Adrenergic beta agonists; Anti bacterial agents; Anticonvulsants; Antidepressive agents; Benzodiazepines; Bone; Calcium channel blockers; Drug toxicity; European medicines agency; Fractures; Liver injury; Myocardial infarction; Neoplasms; Observational studies; Pharmacoepidemiology; Suicide

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTIINFECTIVE AGENT; BENZODIAZEPINE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CALCIUM CHANNEL BLOCKING AGENT;

ACUTE HEART INFARCTION; ARTICLE; COHORT ANALYSIS; DRUG RESEARCH; EUROPE; HIP FRACTURE; HUMAN; LIVER INJURY; MEDICAL RESEARCH; METHODOLOGY; NEOPLASM; PHARMACOEPIDEMIOLOGY; PRIORITY JOURNAL; PROCESS DESIGN; RISK BENEFIT ANALYSIS; STANDARDIZATION; SUICIDE; SUICIDE ATTEMPT; TREATMENT OUTCOME; DRUG SURVEILLANCE PROGRAM; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; EPIDEMIOLOGY; FACTUAL DATABASE; PROCEDURES; REPRODUCIBILITY; RETROSPECTIVE STUDY; RISK ASSESSMENT; STATISTICS AND NUMERICAL DATA;

ADVERSE DRUG REACTION REPORTING SYSTEMS; DATABASES, FACTUAL; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; EUROPE; HUMANS; PHARMACOEPIDEMIOLOGY; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; RISK ASSESSMENT;

EID: 84903489724     PISSN: 15748847     EISSN: None     Source Type: Journal    
DOI: 10.2174/1574884708666131111211802     Document Type: Article

References (74)

1. Strom BL, Kimmel SE, Hennessy S. Pharmacoepidemiology. 5th ed. Wiley-Blackwell: Oxford 2012.
2. Strom BL. Pharmacoepidemiology: Response to a challenge. Pharmacoepidemiol Drug Saf 1995; 4: 11-4.
3. Horwitz RI, Feinstein AR. The problem of "protopathic bias" in case-control studies. Am J Med 1980; 68: 255-8.
4. Lewis MA. The epidemiology of oral contraceptive use: a critical review of the studies on oral contraceptives and the health of young women. Am J Obstet Gynecol 1998; 179: 1086-97.
5. Taubes G. Epidemiology faces its limits. Science 1995; 269: 164-9.
6. Klungel OH, Martens EP, Psaty BM, et al. Methods to assess intended effects of drug treatment in observational studies are reviewed. J Clin Epidemiol 2004; 57: 1223-31.
7. CPRD. The UK Clinical Practice Research Datalink. http: //www.cprd.com/intro.asp (Accessed December 11 2013).
8. Meier CR, Schlienger RG, Kraenzlin ME, Schlegel B, Jick H. HMG-CoA reductase inhibitors and the risk of fractures. JAMA 2000; 283: 3205-10.
9. van Staa TP, Wegman S, de Vries F, Leufkens B, Cooper C. Use of statins and risk of fractures. JAMA 2001; 285: 1850-5.
10. de Vries F, de Vries C, Cooper C, Leufkens B, van Staa TP. Reanalysis of two studies with contrasting results on the association between statin use and fracture risk: the General Practice Research Database. Int J Epidemiol 2006; 35: 1301-8.
11. Guess HA. Exposure-time-varying hazard function ratios in casecontrol studies of drug effects. Pharmacoepidemiol Drug Saf 2006; 15: 81-92.
12. Klungel OH, Stricker BH, Breteler MM, Seidell JC, Psaty BM, de Boer A. Is drug treatment of hypertension in clinical practice as effective as in randomized controlled trials with regard to the reduction of the incidence of stroke? Epidemiology 2001; 12: 339-44.
13. Martens EP, de Boer A, Pestman WR, Belitser SV, Stricker BH, Klungel OH. Comparing treatment effects after adjustment with multivariable Cox proportional hazards regression and propensity score methods. Pharmacoepidemiol Drug Saf 2008; 17: 1-8.
14. Martens EP, Pestman WR, de Boer A, Belitser SV, Klungel OH. Systematic differences in treatment effect estimates between propensity score methods and logistic regression. Int J Epidemiol 2008; 37: 1142-7.
15. Suissa S. Immortal time bias in observational studies of drug effects. Pharmacoepidemiol Drug Saf 2007; 16: 241-9.
16. Hubbard RB, Smith CJ, Smeeth L, Harrison TW, Tattersfield AE. Inhaled corticosteroids and hip fracture: a population-based casecontrol study. Am J Respir Crit Care Med 2002; 166: 1563-6.
17. van Staa TP, Leufkens B, Cooper C. Bone loss and inhaled glucocorticoids. N Engl J Med 2002; 346: 533-5.
18. Schlienger RG, Kraenzlin ME, Jick SS, Meier CR. Use of betablockers and risk of fractures. JAMA 2004; 292: 1326-32.
19. de Vries F, Souverein PC, Cooper C, Leufkens HG, van Staa TP. Use of beta-blockers and the risk of hip/femur fracture in the United Kingdom and The Netherlands. Calcif Tissue Int 2007; 80: 69-75.
20. Cardwell CR, Abnet CC, Cantwell MM, Murray LJ. Exposure to oral bisphosphonates and risk of esophageal cancer. JAMA 2010; 304: 657-63.
21. Green J, Czanner G, Reeves G, Watson J, Wise L, Beral V. Oral bisphosphonates and risk of cancer of oesophagus, stomach, and colorectum: case-control analysis within a UK primary care cohort. BMJ 2010; 341: c4444.
22. Yang YX, Lewis JD, Epstein S, Metz DC. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA 2006; 296: 2947-53.
23. Kaye JA, Jick H. Proton pump inhibitor use and risk of hip fractures in patients without major risk factors. Pharmacotherapy 2008; 28: 951-9.
24. de Vries F, van Staa TP, Leufkens HG. Proton pump inhibitors, fracture risk and selection bias: three studies, same database, two answers. Osteoporos Int 2010; 22: 1641-2.
25. de Vries F, Cooper AL, Cockle SM, van Staa TP, Cooper C. Fracture risk in patients receiving acid-suppressant medication alone and in combination with bisphosphonates. Osteoporos Int 2009; 20: 1989-98.
26. Pharmacoepidemiological Research on Outcomes of Therapeutics by a European Consortium (PROTECT). http://www.imi-protect.eu (Accessed December 11 2013).
27. Foundation for the National Institutes of Health. Observational Medical Outcomes Partnership (OMOP). http://omop.fnih.org (Accessed December 11 2013).
28. European Network of Centres for Pharmacoepidemiology and Pharmacovigilance. http://www.encepp.eu (Accessed December 11 2013).
29. The US Food and Drug Administration. FDA's Sentinel Initiative. http://www.fda.gov/Safety/FDAsSentinelInitiative (Accessed December 11 2013).
30. Trifiro G, Pariente A, Coloma PM, et al. Data mining on electronic health record databases for signal detection in pharmacovigilance: which events to monitor? Pharmacoepidemiol Drug Saf 2009; 18: 1176-84.
31. Stang PE, Ryan PB, Racoosin JA, et al. Advancing the science for active surveillance: rationale and design for the Observational Medical Outcomes Partnership. Ann Intern Med 2010; 153: 600-6.
32. Grimaldi-Bensouda L, Rossignol M, Aubrun E, Benichou J, Abenhaim L. Agreement between patients' self-report and physicians' prescriptions on nonsteroidal anti-inflammatory drugs and other drugs used in musculoskeletal disorders: the international Pharmacoepidemiologic General Research eXtension database. Pharmacoepidemiol Drug Saf 2012; 21: 753-9.
33. European Heart Network. New European Cardiovascular Disease Statistics 2012. http://www.ehnheart.org/cvd-statistics (Accessed December 11 2013)
34. European Commission Eurostat. Statistics Public Health: main tables. http://epp.eurostat.ec.europa/tgm/table.do?tab=table&init=1& language=en&pcode=tps00119&plugin=1 (Accessed December 11 2013).
35. Health in Europe: Information and Data Interface: cardiovascular diseases https: //webgate.ec.europa.eu/sanco/heidi/index.php/Heidi/ Major_and_chronic_diseases/Cardiovascular_disease/Ischaemic_he art_disease (Accessed December 11 2013).
36. Ibanez L, Perez E, Vidal X, Laporte JR. Prospective surveillance of acute serious liver disease unrelated to infectious, obstructive, or metabolic diseases: epidemiological and clinical features, and exposure to drugs. J Hepatol 2002; 37: 592-600.
37. de Abajo FJ, Montero D, Madurga M, Garcia Rodriguez LA. Acute and clinically relevant drug-induced liver injury: a population based case-control study. Br J Clin Pharmacol 2004; 58: 71-80.
38. Sgro C, Clinard F, Ouazir K, et al. Incidence of drug-induced hepatic injuries: a French population-based study. Hepatology 2002; 36: 451-5.
39. Shapiro MA, Lewis JH. Causality assessment of drug-induced hepatotoxicity: promises and pitfalls. Clin Liver Dis 2007; 11: 477-505.
40. Lexchin J. Drug withdrawals from the Canadian market for safety reasons, 1963-2004. CMAJ 2005; 172: 765-7.
41. Giezen TJ, Mantel-Teeuwisse AK, Straus SM, Schellekens H, Leufkens HG, Egberts AC. Safety-related regulatory actions for biologicals approved in the United States and the European Union. JAMA 2008; 300: 1887-96.
42. Vuppalanchi R, Liangpunsakul S, Chalasani N. Etiology of newonset jaundice: how often is it caused by idiosyncratic druginduced liver injury in the United States? Am J Gastroenterol 2007; 102: 558-62.
43. Slavin DE, Schlichting CL, Freston JW. Rating the severity of the medical consequences of drug-induced liver injury. Regul Toxicol Pharmacol 2005; 43: 134-40.
44. International Osteoporosis Foundation. Osteoporosis in Europe: Indicators of Progress Outcomes of panel meeting 2005 Nov 10, 2004: http: //www.iofbonehealth.org/osteoporosis-europe-inbdicatorsprogress-2005 (Accessed December 11 2013).
45. Cooper C, Atkinson EJ, Jacobsen SJ, O'Fallon WM, Melton LJ, 3rd. Population-based study of survival after osteoporotic fractures. Am J Epidemiol 1993; 137: 1001-5.
46. Leibson CL, Tosteson AN, Gabriel SE, Ransom JE, Melton LJ. Mortality, disability, and nursing home use for persons with and without hip fracture: a population-based study. J Am Geriatr Soc 2002; 50: 1644-50.
47. European Medicines Agency. European Public Assessment Reports (EPAR): antiretroviral: http://www.ema.europa.eu/docs/en_GB/ document_library/EPAR_-_Product_Information/human/000797/ WC500028102.pdf (Accessed December 11 2013).
48. European Medicines Agency. European Public Assessment Reports (EPAR): pioglitazone: http: //www.ema.europa.eu/docs/en_GB/ document_library/Other/2011/07/WC500109185.pdf (Accessed December 11 2013).
49. European Medicines Agency. Summary of product charactersitics: rosiglitazone: http://www.ema.europa.eu/docs/en_GB/document_ library/EPAR_-_Product_Information/human/000268/WC00029108. pdf (Accessed December 11 2013).
50. Schroder HM, Petersen KK, Erlandsen M. Occurrence and incidence of the second hip fracture. Clin Orthop Relat Res 1993; 289: 166-9.
51. Statistics Netherlands: http: //statline.cbs.nl/StatWeb/publication/? DM=SLNL&PA=71859NED&D1=1,3,5,7-8&D2=1-2&D3=1& D4=189&D5=l&VW=T (Accessed December 11 2013).
52. European Commission EUROSTAT. Death due to suicide, by gender 2010 November 2012: http: //epp.eurostat.ec.europa/tgm/ table.do?tab=table&init=1language=en&pcode=tps00122&plugin=1. (Accessed December 11 2013).
53. Health in Europe: Information and Data Interface: Cancer. http: //webgate.ec.europa.eu/sanco/heidi/index.php/Heidi/Major_and_ch ronic_diseases/ Cancer#Adult_cancer_survival. (Accessed December 11 2013).
54. Statens Serum Institut. Register of Medicinal Product Statistics. http: //www.medstat.dk/en. (Accessed December 11 2013).
55. Norwegen Prescription Database.: http://www.norpd.no/prevalens. aspx. (Accessed December 11 2013).
56. GIPdatabank. The Drug Information System of the Health Care Insurance Board The Netherland: http://www.gipdatabank.nl. (Accessed December 11 2013).
57. Salpeter SR. Cardiovascular safety of beta(2)-adrenoceptor agonist use in patients with obstructive airway disease: a systematic review. Drugs Aging 2004; 21: 405-14.
58. Salpeter SR, Buckley NS, Salpeter EE. Meta-analysis: anticholinergics, but not beta-agonists, reduce severe exacerbations and respiratory mortality in COPD. J Gen Intern Med 2006; 21: 1011-9.
59. Cates CJ, Lasserson TJ, Jaeschke R. Regular treatment with salmeterol and inhaled steroids for chronic asthma: serious adverse events. Cochrane Database Syst Rev 2009(3): CD006922.
60. Cates CJ, Lasserson TJ, Jaeschke R. Regular treatment with formoterol and inhaled steroids for chronic asthma: serious adverse events. Cochrane Database Syst Rev 2009(2): CD006924.
61. de Vries F, Pouwels S, Bracke M, et al. Use of beta2 agonists and risk of acute myocardial infarction in patients with hypertension. Br J Clin Pharmacol 2008; 65: 580-6.
62. Zhang B, de Vries F, Setakis E, van Staa TP. The pattern of risk of myocardial infarction in patients taking asthma medication: a study with the General Practice Research Database. J Hypertens 2009; 27: 1485-92.
63. Neil Kaplowitze LDD. Drug-induced Liver Disease. 1 ed. Informa Healthcare; 2003.
64. Sabate M, Ibanez L, Perez E, et al. Risk of acute liver injury associated with the use of drugs: a multicentre population survey. Aliment Pharmacol Ther 2007; 15: 25: 1401-9.
65. Ginzburg R, Rosero E. Risk of fractures with selective serotoninreuptake inhibitors or tricyclic antidepressants. Ann Pharmacother 2009; 43: 98-103.
66. Allain H, Bentue-Ferrer D, Polard E, Akwa Y, Patat A. Postural instability and consequent falls and hip fractures associated with use of hypnotics in the elderly: a comparative review. Drugs Aging 2005; 22: 749-65.
67. MHRA Medicines and Healthcare products Regulatory Agency. Drug Safety Update Antidepressants: risk of fractures 2010. http: //www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON08 5136. (Accessed December 11 2013).
68. US Food and Drug Agency. Statistical Review and Evaluation: Antiepleptic Drugs and Suicidality: http: //www.fda.gov/downloads/ Drugs/DrugSafety/PostmarketDrugSafetyInformationd for Patients and Providers/UCM192556.pdf. (Accessed December 11 2013).
69. Andersohn F, Schade R, Willich SN, Garbe E. Use of antiepileptic drugs in epilepsy and the risk of self-harm or suicidal behavior. Neurology 2010; 75: 335-40.
70. Arana A, Wentworth CE, Ayuso-Mateos JL, Arellano FM. Suiciderelated events in patients treated with antiepileptic drugs. N Engl J Med 2010; 363: 542-51.
71. Patorno E, Bohn RL, Wahl PM, et al. Anticonvulsant medications and the risk of suicide, attempted suicide, or violent death. JAMA 2010; 303: 1401-9.
72. Pahor M, Guralnik JM, Ferrucci L, et al. Calcium-channel blockade and incidence of cancer in aged populations. Lancet 1996; 348: 493-7.
73. Fitzpatrick AL, Daling JR, Furberg CD, Kronmal RA, Weissfeld JL. Use of calcium channel blockers and breast carcinoma risk in postmenopausal women. Cancer 1997; 80: 1438-47.
74. Beiderbeck-Noll AB, Sturkenboom MC, van der Linden PD, et al. Verapamil is associated with an increased risk of cancer in the elderly: the Rotterdam study. Eur J Cancer 2003; 39: 98-105.